DSY Dassault Systemes SA

Dassault Systèmes: Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey

Dassault Systèmes: Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey

Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey 

Expanded 10-plus-year collaboration will leverage Medidata Experiences, enabling Sanofi to streamline operations, refine data quality, and enhance patient care

New York – Oct. 23, 2025 –, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, and today announced an expansion of their partnership to bolster clinical research. This new agreement will take advantage of the , building on both organizations’ shared vision to boost innovation in studies, speed new therapies to market, and promote health outcomes for people globally.

The Medidata Experiences address the fragmented, standalone tools of the life sciences industry by offering AI-embedded, platform-based solutions across clinical workflows, unifying trial processes, diminishing silos, and reducing costs and delays. Combining these Experiences with Sanofi’s pharmaceutical knowledge will advance studies, amplifying the development of therapies with greater precision and impact.

“Sanofi and Medidata have worked together for a decade within clinical research, including a in 2024,” said Gaelan Ritter, global head of digital clinical development, Sanofi. “With this broadened relationship, we will continue harnessing the power of AI, optimizing our clinical trials, and ultimately expediting the delivery of groundbreaking medicines.”

Sanofi will employ Medidata’s expertise and capabilities in as part of this new enterprise agreement. Medidata will also provide strategic consulting and end-to-end operational support, empowering Sanofi to further streamline research processes.

“Clinical development is complex, and biopharma companies demand a strategic partner who can help them enhance data quality, improve study design, and elevate patient care," said Lisa Moneymaker, chief strategy officer, Medidata. "Through our alliance, Sanofi can leverage our unified solutions, specifically mapped out to meet their core needs, to simplify execution and accelerate the entire clinical development process.”

To learn more about the Medidata Experiences, please visit .

About Medidata

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 36,000 trials and 11 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and one of the largest clinical trial data sets in the industry. More than 1 million registered users across approximately 2,300 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at . Listen to our latest podcast, , and follow us at @Medidata.

About Dassault Systèmes

Dassault Systèmes is a catalyst for human progress. Since 1981, the company has pioneered virtual worlds to improve real life for consumers, patients and citizens. With Dassault Systèmes’ 3DEXPERIENCE platform, 370,000 customers of all sizes, in all industries, can collaborate, imagine and create sustainable innovations that drive meaningful impact. For more information, visit: .

About Sanofi

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Contact:

Medidata PR

Analyst Relations

Sanofi PR

Sandrine Guendoul |

Evan Berland |

Léo Le Bourhis |

Victor Rouault |

Timothy Gilbert |

Léa Ubaldi |

Attachment



EN
23/10/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Dassault Systemes SA

 PRESS RELEASE

Dassault Systèmes: Half-year statement of the Liquidity contract enter...

Dassault Systèmes: Half-year statement of the Liquidity contract entered into with Oddo BHF SCA Press ReleaseVELIZY-VILLACOUBLAY, France — January 12, 2026 Half-year statement of the Liquidity contract entered into with Oddo BHF SCA (Euronext Paris: FR0014003TT8, DSY.PA) announces that the following resources appeared on December 31, 2025 on the liquidity contract entered into with Oddo BHF SCA implemented on January 7, 2015 and updated on June 18, 2019:      925,197 Dassault Systèmes shares, and€ 5,384,754.01 in cash. It is reminded that: at the time of the implementation of the liqu...

 PRESS RELEASE

Dassault Systèmes : Bilan Semestriel du Contrat de Liquidité conclu av...

Dassault Systèmes : Bilan Semestriel du Contrat de Liquidité conclu avec Oddo BHF SCA Communiqué de PresseVELIZY-VILLACOUBLAY, France — le 12 janvier 2026 Bilan Semestriel du Contrat de Liquidité conclu avec Oddo BHF SCA (Euronext Paris : FR0014003TT8, DSY.PA) annonce qu’au titre du contrat de liquidité confié à Oddo BHF SCA mis en œuvre depuis le 7 janvier 2015 et mis à jour le 18 juin 2019, les moyens suivants figuraient au compte de liquidité à la date du 31 décembre 2025 : 925 197 actions Dassault Systèmes, et5 384 754,01 € en espèces. Il est rappelé : qu’à l’ouverture du contrat ...

 PRESS RELEASE

Declaration of the number of outstanding shares and voting rights as ...

Declaration of the number of outstanding shares and voting rights as of December 31, 2025 Press ReleaseVELIZY-VILLACOUBLAY, France — January 7, 2026                 Declaration of the number of outstanding shares and voting rights as of December 31, 2025 (Euronext Paris: FR0014003TT8, DSY.PA) today announced below the total number of its outstanding shares and voting rights as of December 31, 2025, according to articles 223-16 and 221-3 of the General Regulation of the Autorité des marchés financiers. Number of outstanding shares: 1,341,806,268 Number of voting rights*: 2,013,578,477 ...

 PRESS RELEASE

Déclaration du nombre d’actions et de droits de vote au 31 décembre 20...

Déclaration du nombre d’actions et de droits de vote au 31 décembre 2025 Communiqué de PresseVELIZY-VILLACOUBLAY, France — le 7 janvier 2026 Déclaration du nombre d’actions et de droits de voteau 31 décembre 2025         (Euronext Paris : FR0014003TT8, DSY.PA) annonce ci-après le nombre total d’actions composant son capital et le nombre total de ses droits de vote au 31 décembre 2025, conformément aux articles 223-16 et 221-3 du Règlement Général de l’Autorité des marchés financiers. Nombre d'actions en circulation : 1 341 806 268 Nombre de droits de vote* : 2 013 578 477 *Ce nombre t...

Dassault Systemes Sa: 1 director

A director at Dassault Systemes Sa bought 32,355 shares at 23.075EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch